Flow cytometry analysis revealed that within CD8+T cells, the median CD8+MAIT cells level in the population of patients with metastatic NSCLC was 15.1%; thus, this value was used as a cutoff to stratify patients. This evidence concerns the gene CD8A and non-small cell lung carcinoma.